ArticleJournal for immunotherapy of cancer2026

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Francois Ghiringhelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.